PCI-27483 is primarily investigated for its potential in cancer therapy, particularly as a factor VIIa inhibitor. It targets the coagulation pathway, which is often hijacked by tumors to promote growth and metastasis. By inhibiting factor VIIa, PCI-27483 disrupts the signaling cascade that supports tumor progression, making it a promising candidate for treating cancers that rely on this pathway. Its application is especially relevant in pancreatic cancer, where coagulation factors play a significant role in disease progression. Research is ongoing to evaluate its efficacy and safety in clinical settings.